California Psilocybin Decriminalization Initiative The Beckley Foundation is proud to announce its partnership with Decriminalize California (the California Psilocybin Decriminalization Initiative 2020), an open-source citizens’ initiative which would: legalize psilocybin mushrooms and their extracts and derivatives for therapeutic and medical use, and decriminalize it for personal, spiritual and religious use; allowing people to cultivate and use psilocybin mushrooms in their own home and on privately-owned property; and enabling those convicted of psilocybin-related crimes to have their sentences reviewed and, when appropriate, have their criminal records expunged. You can read the full press release here. The initiative decriminalizes psilocybin use by adults aged 18+. [...]
Lire la suiteDrugs, Religion, and Cultural Heritage : An Analysis of the Public Policies Regarding the Use of Ayahuasca in Brazil Henrique Fernandes Antunes The International Journal of Religion and Spirituality in Society, 2018, Volume #, Issue #, http://doi.org/###################### Abstract : In 1985, ayahuasca was banned for a short period of time by the Federal Council of Drugs (CONFEN). After more than two decades of debates and public policies, the Brazilian government consolidated the regulation of ayahuasca consumption for religious purposes and recognized ayahuasca groups as legitimate religions and part of the cultural heritage of the Amazon region. The aim of this work is to demonstrate that [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L. Robertshaw & Andrew D. Westwell Future medicinal chemistry, February 2019 Doi : 10.4155/fmc-2018-0447 Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required [...]
Lire la suiteNotes from the Field : Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018 Roberta Z. Horth, Barbara Crouch, B. Zane Horowitz, Amelia Prebish, Matthew Slawson, Jennifer McNair, Chris Elsholz, Stephen Gilley, Jenny Robertson, Ilene Risk, Mary Hill, Linnea Fletcher, Wei Hou, Dallin Peterson, Karlee Adams, Dagmar Vitek, Allyn Nakashima, Angela Dunn MMWR / May 25, 2018 / Vol. 67 / No. 20 US Department of Health and Human Services/Centers for Disease Control and Prevention On December 8, 2017, the Utah Poison Control Center (UPCC) notified the Utah Department of Health (UDOH) of reports of emergency department visits associated with reported [...]
Lire la suiteTrends in Internet Searches for Cannabidiol (CBD) in the United States Eric C. Leas, Alicia L. Nobles, PhD, Theodore L. Caputi, Mark Dredze, DaveyM. Smith, JohnW. Ayers JAMA Network Open, 2019, 2, (10), e1913853. doi: 10.1001/jamanetworkopen.2019.13853 Introduction Cannabidiol (CBD) is widely promoted as a panacea. For example, the cannabis brand MedMen claims CBD treats acne, anxiety, opioid addiction, pain, and menstrual problems.1 However, the US Food and Drug Administration has only approved highly purified CBD (Epidiolex) for treating epilepsy. To our knowledge, there is currently no population-focused surveillance of public interest in CBD. Consequently, many question whether CBD should be prioritized by public health leaders [...]
Lire la suiteCannabis thérapeutique : si tout va bien il ne sera pas disponible avant un certain temps Journalisme et Santé Publique Le blog de Jean-Yves Nau, journaliste et docteur en médecine 17 Octobre 2019 https://jeanyvesnau.com/2019/10/17/cannabis-therapeutique-si-tout-va-bien-il-ne-sera-pas-disponible-avant-un-certain-temps/ Bonjour Le temps de l’administration du médicament n’est pas celui du patient souffrant. Il y a un an on découvrait un mouvement de l’Agence nationale de sécurité médicament (ANSM) : « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis thérapeutique en France ». On apprenait alors qu’un Comité Scientifique Spécialisé Temporaire créé pour un an, aurait pour mission « d’évaluer la pertinence de développer en France l’utilisation thérapeutique du cannabis pour [...]
Lire la suiteRenseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Santé Canada Auteur : Hanan Abramovici Ph.D. Co-auteurs : Sophie-Anne Lamour, Ph.D. et George Mammen, Ph.D. Nous republions cet excellent document de Santé Canada, et surtout, le résumé des indications reconnues, et envisagées, du cannabis thérapeutique. Aperçu des énoncés récapitulatifs Les énoncés récapitulatifs suivants visent à résumer le contenu des sections 4.0 (Usages thérapeutiques possibles) et 7.0 (Effets indésirables) et leurs sous-sections respectives. Les énoncés récapitulatifs peuvent être également trouvés dans leurs sections et sous-sections respectives dans le corps même du document. Remarque: la plupart des études [...]
Lire la suiteLong-term Heavy Cannabis Use : implications for health education Niall COGGANS, Phil DALGARNO, Lindsay JOHNSON & David SHEWAN Drugs : education, prevention and policy, 2004, Vol. 11, No. 4, 299–313 ABSTRACT There is growing evidence that cannabis can have negative effects on health. While the ongoing debate about the nature and duration of these effects recognizes mild cognitive impairment, the evidence for irreversibility of cognitive impairment and causal links with psychiatric illness is not conclusive. There is undoubtedly potential for impairment of respiratory functioning, but that will depend on lifetime load and in most cases is confounded with tobacco smoking. There is a [...]
Lire la suiteThe association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]
Lire la suiteEpidemiology of adolescent Salvia divinorum use in Canada Cheryl L. Currie Drug and Alcohol Dependence, 2012, 128, (1-2) DOI: 10.1016/j.drugalcdep.2012.08.008 a b s t r a c t Background : Salvia divinorum is a potent, naturally occurring hallucinogen gaining popularity as a recreational drug in North America. To date, detailed epidemiologic information about the use of this substance among adolescents living outside the United States has been limited. This study provides information on the prevalence and correlates of Salvia divinorum use among adolesecents in Canada using a nationally representative sample. Methods : Data were obtained from a representative sample of 42,179 Canadian adolescents aged 12–17 years living [...]
Lire la suite